Eva Temkin, a former director for policy at the FDA’s Office of Therapeutic Biologics and Biosimilars, has joined Paul Hastings, after practicing for three years at King & Spalding. She will head up Paul Hasting’s FDA practice out of Washington, D.C.

Paul Hastings has an existing FDA practice, but the hiring of Temkin illustrates how firms are sharpening their regulatory practices in a bid to further support all firm groups, especially in the life sciences/pharma/biotech space in deal work. Regulations and compliance with them can determine a company’s fate.